Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Running, not enrolling · Phase 2
Conditions studied: Diffuse Large B-cell Lymphoma
In brief
A multicenter, open-label Phase 2b study of selinexor (KPT-330) in participants with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have no therapeutic options of demonstrated clinical benefit.
Key facts
- Study ID
- NCT02227251
- Run by
- Karyopharm Therapeutics Inc
- People needed
- 244
- Starts
- 2014-11-01
- Expected to finish
- 2026-12-01
- Last updated by the study team
- 2026-07-02
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of California San Francisco — San Francisco, California, United States
- University of California Los Angeles (UCLA) — Santa Monica, California, United States
- Boca Raton Cancer Research Medical Center — Plantation, Florida, United States
- University of Chicago — Chicago, Illinois, United States
- Robert H. Lurie Comprehensive Cancer Center/Northwestern University — Chicago, Illinois, United States
- Norton Cancer Institute — Louisville, Kentucky, United States
- Dana Farber Cancer Institute — Boston, Massachusetts, United States
- Tufts Medical Center — Boston, Massachusetts, United States
- Lahey Clinic — Burlington, Massachusetts, United States
- University of Massachusetts Medical School — Worcester, Massachusetts, United States
- John Theurer Cancer Center at Hackensack University Medical Center — Hackensack, New Jersey, United States
- Clinical Research Alliance — Lake Success, New York, United States
- New York Presbyterian Hospital/ Cornell Medical College — New York, New York, United States
- Stony Brook University Hospital — Stony Brook, New York, United States
- Gabrail Cancer Center — Canton, Ohio, United States
- Cleveland Clinic Foundation — Cleveland, Ohio, United States
- University Hospitals Seidman Cancer Center — Cleveland, Ohio, United States
- University of Oklahoma — Oklahoma City, Oklahoma, United States
- Greenville Hospital System — Greenville, South Carolina, United States
- MD Anderson — Houston, Texas, United States
- Swedish Cancer Institute — Seattle, Washington, United States
- Virginia Mason Hospital & Medical Center — Seattle, Washington, United States
- St. Vincent's Hospital Sydney — Darlinghurst, New South Wales, Australia
- Liverpool Hospital, Ingham Institute of Medical Research — Liverpool, New South Wales, Australia
- UACC Arizona — Tucson, Arizona, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.